TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort

被引：1
|
作者：
Yuan, J. [1 ]
Zheng, Y. [2 ]
Xu, L. [3 ]
Xie, F. [4 ]
Gu, S. [5 ]
Li, Q. [6 ]
Zhang, J. [7 ]
Ba, Y. [8 ]
Huaxin, D. [9 ]
Yang, A. [10 ]
Li, J. [10 ]
Zhou, J. [11 ]
Shen, L. [11 ]
机构：
[1] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp Inst, Beijing, Peoples R China
[2] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[4] Chinese PLA Naval Mil Med Univ, Dept Surg, Affiliated Hosp 3, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Intervent Div, Changsha, Peoples R China
[6] SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China
[7] Southern Med Univ, Dept Oncol, ZhuJiang Hosp, Zhujiang, Peoples R China
[8] Tianjin Med Univ, Dept Gastroenterol, Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hunan Prov Peoples Hosp, Dept Oncol, Changsha, Peoples R China
[10] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Med, Lianyungang, Peoples R China
[11] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [11] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720
  • [12] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
    Stein, Eytan M.
    Dinardo, Courtney Denton
    Pollyea, Daniel Aaron
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    Flinn, Ian
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Stein, Anthony Selwyn
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Knight, Robert D.
    Agresta, Samuel V.
    De Botton, Stephane
    Tallman, Martin S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [13] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Cloughesy, Timothy Francis
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory Michael
    De La Fuente, Macarena Ines
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Zhang, Yanwei
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi Sumant
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
    Fan, B.
    Chen, Y.
    Wang, F.
    Yen, K.
    Utley, L.
    Prahl, M.
    Colby, K.
    Straley, K.
    Bowden, C.
    Biller, S.
    Agresta, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 218 - 218
  • [15] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
    Roboz, Gail J.
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Mims, Alice S.
    Prince, Gabrielle T.
    Altman, Jessica K.
    Arellano, Martha L.
    Donnellan, William B.
    Erba, Harry P.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Watts, Justin M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Tallman, Martin S.
    Choe, Sung
    Dai, David
    Fan, Bin
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Hickman, Denice
    Liu, Hua
    Agresta, Samuel V.
    Wu, Bin
    Attar, Eyal C.
    Stone, Richard M.
    BLOOD, 2018, 132
  • [16] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
    Fan, Bin
    Le, Kha
    Manyak, Erika
    Liu, Hua
    Prahl, Malia
    Bowden, Chris J.
    Biller, Scott
    Agresta, Sam
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [17] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [18] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
    Mellinghoff, Ingo
    Penas-Prado, Marta
    Peters, Katherine
    Cloughesy, Timothy
    Burris, Howard
    Maher, Elizabeth
    Janku, Filip
    Cote, Gregory
    De La Fuente, Macarena
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Xu, Huansheng
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi
    Wen, Patrick
    NEURO-ONCOLOGY, 2018, 20 : 18 - 18
  • [19] Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    Foran, James M.
    DiNardo, Courtney D.
    Watts, Justin M.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony
    Stone, Richard M.
    Patel, Prapti A.
    Tallman, Martin S.
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Fan, Bin
    Yen, Katharine E.
    Oluyadi, Abdulafeez
    Winkler, Thomas
    Hickman, Denice
    Agresta, Samuel V.
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [20] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Roboz, Gail J.
    Altman, Jessica K.
    Mims, Alice S.
    Swords, Ronan
    Collins, Robert H.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Donnellan, Will
    Fathi, Amir T.
    Pigneux, Arnaud
    Erba, Harry P.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Willekens, Christophe
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Yang, Hua
    Dai, David
    Fan, Bin
    Goldwasser, Meredith
    Liu, Hua
    Agresta, Sam
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
12345